Through the Development of a Universal Technology for Adult Stem Cell Production, Asymmetrex will Accelerate Regenerative Medicine. Background for the “Suppression of Asymmetric Cell Kinetics (SACK)” Technology Asymmetrex’s solution to the adult tissue stem cell production problem is based on a seminal insight by its founder. In a 2001 research report, Dr. Sherley and his
Asymmetrex’s AlphaSTEM Technology Is A First-Ever Technology For Quantitative Analysis Of Adult Tissue Stem Cells That Will Accelerate Progress In Stem Cell Biomedicine Click here to download a slide deck with the most recent technological benchmarks. Posted October 27, 2015 Overview Asymmetrex, LLC and AlphaSTAR Corporation (ASC) have partnered to develop a first-of-its-kind computer simulation-primary cell culture
Now that Massachusetts stem cell biotechnology company Asymmetrex has developed the first and only technology for specific and accurate counting of therapeutic tissue stem cells, today the company has launched a campaign to alert stem cell scientists, physicians, and patients to the long unmet need of a means to count tissue stem cells. The major
No matter what the specific discipline, the best scientific research strives to be quantitative. Throughout research and practice in science, engineering, and medicine, measuring the focus of investigation is an implicit essential principle. In cell biology, this crucial application is cell counting. How are cell counts calculated? In all cell counting methods, three general steps
The founder and director of stem cell biotechnology company Asymmetrex, James L. Sherley, M.D., Ph.D., continues to lead the company’s public service mission of disseminating timely scientific information on the qualities of tissue stem cells and their use for medical therapies. Most recently, in a July 20 invited essay posted on the Oncology webpage of
For many years, progress in stem cell medicine has been held back because of a lack of effective and efficient methods for the manufacture of therapeutic adult tissue stem cells. Massachusetts stem cell biotechnology company Asymmetrex announces this week that it now offers a new contract service that can help suppliers of therapeutic adult tissue
On March 8-9 in Boston, stem cell medicine biotechnology start-up Asymmetrex led attendees at the 6th Annual Clinical Trials Supply New England 2017 conference in discussions about the need for quality controls for the supply of tissue stem cells used for treatments in either FDA-approved clinical trials or unregulated private stem cell clinics. Though these
Boston’s stem cell medicine biotechnology start-up Asymmetrex is beginning 2017 with exciting news for its recently launched contract service for counting adult tissue stem cells. The company’s webinar, produced with the international regenerative medicine social media network RegMedNet to describe Asymmetrex’s new counting technology and its applications, was 4th among the 10 most popular content
The biotech medicine world has been waiting to hear from new gene-editing companies exactly how they will go about turning the highly touted research advance into an effective medical advance. If reports about gene-editing company Intellia Therapeutics’ plan are any indication of the approach that will be taken, there is a rocky road ahead for
During the fall regenerative medicine and pharmaceutical conference seasons, Boston biotechnology company Asymmetrex, LLC will announce its new contract service for counting adult tissue stem cells. In three different conference venues, the company will relate how its new AlphaSTEM Test service can provide, for the first time, stem cell dose data for stem cell treatments